In this multi‐center real‐world data study, we analyzed the clinical efficacy of first‐line BRAF/MEKi, Anti‐PD‐1, and PD‐1/CTLA‐4 therapies in 336 Asian patients with advanced BRAF V600‐mutant melanoma. This evidence concerns the gene BRAF and melanoma.